Home > News > Headline News > Archive

Click on title to read the full article.

Perspective: The right trials

May 31, 2012

By Patricia S. Steeg, Nature magazine

The system for clinical trials must be redesigned if there is to be a decline in breast cancer metastasis, argues Patricia S. Steeg.

Prevalence and characteristics of patients with stage IV solid tumors who receive no anticancer therapy.

May 29, 2012

By ASCO 2012

Clinicians caring for patients with cancer are well aware that a subset of patients who present with metastatic solid tumors never receive anticancer therapy for reasons including poor functional status, comorbidities, and patient preference. The prevalence and characteristics of this population have not previously been described.

In their findings to be presented at June ASCO in Chicago, researchers concluded age, race, income and insurance status were factors, in addition to patient preference. For metastatic breast cancer, 12.4% were untreated.

ASCO: Stage IV Cancer Often Not Treated

May 24, 2012

By John Gever, Senior Editor, MedPage Today

CHICAGO -- One patient in five who presents with a stage IV solid-tumor cancer does not receive treatment directed at the cancer, researchers found.

Anti-cancer treatment for newly diagnosed metastatic disease varied significantly according to factors that may not be related to informed preferences for treatment, according to Matthew Galsky, MD, of Mount Sinai School of Medicine in New York City, and colleagues

 

Limits to growth: Scientists identify key metastasis-enabling enzyme

May 23, 2012

By Stuart Mason Dambrot, Medical Xpress

On the complex road to eradicating cancer, controlling or preventing metastatic growth initiated by primary tumors is high on the to-do list. A key area of such research is the development of therapies based on identifying markers of metastasis associated with altered choline metabolism in breast, ovarian, and prostate cancers.

'Fertilizing' bone marrow helps answer why some cancers spread to bones

May 16, 2012

By Laura Bailey, University of Michigan

Ann Arbor, Mich: Researchers found that administering a common chemotherapy drug before bone tumors took root actually fertilized the bone marrow, enabling cancer cells, once introduced, to seed and grow more easily.

HER2-targeting affibody bests FDG for imaging pulmonary metastases

May 15, 2012

By Health Imaging, from Journal of Nuclear Medicine

An affibody which targets human epidermal growth factor receptor 2 (HER2)-expressing breast cancer lesions has been shown to allow early detection of HER2-positive pulmonary metastases and with more specificity than 18F-FDG, according to a study published online May 11 in the Journal of Nuclear Medicine.

Research Center to Focus on Cancer Genes

May 10, 2012

By Denise Grady, New York Times

Couple gives $25 million to University of Pennsylvania, Basser Research Center for research, counseling, cancer prevention and treatment for people with BRCA mutations.

Online study of Avastin breast cancer patients

May 8, 2012

By Victoria Colliver, SFGate online

South San Francisco's Genentech has teamed up with personal genetics company 23andMe for a new kind of study - one that doesn't require patients to find a clinical trial center or make frequent visits to a doctor's office.

Scientists Identify 10 Molecular Types of Breast Cancer -- How Long Until Progress Reaches the Clinic?

May 6, 2012

By Dr. Elaine Schattner, Huffington Post

Dr. Elaine Schattner prods researchers to use the 10 new molecular types as a basis for smarter therapies.

Sorafenib Combo Ups PFS but Toxicity Is High

May 3, 2012

By Charles Bankhead, MedPage Today

Women with advanced breast cancer had 2-month improvement in progression-free survival (PFS) when the targeted drug sorafenib was added to chemotherapy, but toxicity levels were high, results of a placebo-controlled trial showed.

 1 2 >